Polypharmacy and adverse events in atrial fibrillation: Main cause or reflection of multimorbidity?

Background: Previous evidence indicated that atrial fibrillation (AF) patients with polypharmacy presented increased probability of adverse events. We investigated the prevalence of polypharmacy, risk factors for polypharmacy, and the impact of polypharmacy in clinical outcomes in a 'real-world' cohort of AF patients starting vitamin K antagonists (VKAs).

Methods: Prospective study including AF outpatients starting VKA therapy from July, 2016 to June, 2018.